CSS
FENC icon

Cubist Systematic Strategies’s Fennec Pharmaceuticals FENC Stock Holding History

Cubist Systematic Strategies’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,162
Closed -$113K – 3303
2024
Q1 		$113K Buy
+10,162
New +$102K ﹤0.01% 3236
2023
Q2 		– Sell
-11,304
Closed -$94K – 3758
2023
Q1 		$94K Buy
+11,304
New +$105K ﹤0.01% 3454

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Cubist Systematic Strategies's FENC Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Fennec Pharmaceuticals (FENC) in Q2 2024, closing a stake of 10,162 shares — an estimated $113K sold.

Cubist Systematic Strategies first reported a position in FENC in Q1 2023 and held it in 2 quarters. The position peaked at $113K in Q1 2024. 64 funds tracked by Wall St. Rank hold FENC as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Fennec Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 10,162 Fennec Pharmaceuticals shares in Q2 2024, an estimated $113K.
  • Cubist Systematic Strategies first reported a position in Fennec Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Cubist Systematic Strategies's Fennec Pharmaceuticals position peaked at $113K in Q1 2024.
  • 64 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.